Get Real Time Here
| Open22.470 | Close21.540 |
| Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
| Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Beam Therapeutics Stock (NASDAQ:BEAM), Quotes and News Summary
Beam Therapeutics Stock (NASDAQ: BEAM) stock price, news, charts, stock research, profile.
| Open22.470 | Close21.540 |
| Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
| Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.340 | (EXPECTED) 2023-11-06 | |||||
| REV | 17.490M | ||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.420 | -1.080 | 0.3400 | ||||
| REV | 18.050M | 20.116M | 2.066M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-09-13 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
| 2023-08-29 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
| 2023-08-09 | Barclays | Gena Wang | Maintains | Equal-WeightEqual-Weight | Lowers | 41.00 | 35.00 |
| 2023-08-09 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 46.00 | 47.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| BEAM | Beam Therapeutics | -3.75% | 1.7B |
| IDYA | IDEAYA Biosciences | -0.16% | 1.5B |
| RARE | Ultragenyx Pharmaceutical | -3.44% | 2.4B |
| ZNTL | Zentalis Pharma | 3.11% | 1.4B |
| PRTA | Prothena Corp | -4.65% | 2.4B |
How do I buy Beam Therapeutics (BEAM) stock?
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Who are Beam Therapeutics's (BEAM) competitors?
Other companies in Beam Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Zentalis Pharma (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA) and SpringWorks Therapeutics (NASDAQ:SWTX).
What is the target price for Beam Therapeutics (BEAM) stock?
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on Wednesday, September 13, 2023. The analyst firm set a price target for 56.00 expecting BEAM to rise to within 12 months (a possible 159.86% upside). 16 analyst firms have reported ratings in the last year.
Current Stock Price for Beam Therapeutics (BEAM)?
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $21.55 last updated October 4, 2023 at 11:33 PM UTC.
Does Beam Therapeutics (BEAM) pay a dividend?
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
When is Beam Therapeutics (NASDAQ:BEAM) reporting earnings?
Beam Therapeutics’s Q3 earnings are confirmed for Monday, November 6, 2023.
Is Beam Therapeutics (BEAM) going to split?
There is no upcoming split for Beam Therapeutics.
What sector and industry does Beam Therapeutics (BEAM) operate in?
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Beam Therapeutics Stock (NASDAQ:BEAM), Quotes and News Summary
Beam Therapeutics Stock (NASDAQ: BEAM) stock price, news, charts, stock research, profile.
| Open22.470 | Close21.540 |
| Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
| Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.340 | (EXPECTED) 2023-11-06 | |||||
| REV | 17.490M | ||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.420 | -1.080 | 0.3400 | ||||
| REV | 18.050M | 20.116M | 2.066M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-09-13 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
| 2023-08-29 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
| 2023-08-09 | Barclays | Gena Wang | Maintains | Equal-WeightEqual-Weight | Lowers | 41.00 | 35.00 |
| 2023-08-09 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 46.00 | 47.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| BEAM | Beam Therapeutics | -3.75% | 1.7B |
| IDYA | IDEAYA Biosciences | -0.16% | 1.5B |
| RARE | Ultragenyx Pharmaceutical | -3.44% | 2.4B |
| ZNTL | Zentalis Pharma | 3.11% | 1.4B |
| PRTA | Prothena Corp | -4.65% | 2.4B |
How do I buy Beam Therapeutics (BEAM) stock?
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Who are Beam Therapeutics's (BEAM) competitors?
Other companies in Beam Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Zentalis Pharma (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA) and SpringWorks Therapeutics (NASDAQ:SWTX).
What is the target price for Beam Therapeutics (BEAM) stock?
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on Wednesday, September 13, 2023. The analyst firm set a price target for 56.00 expecting BEAM to rise to within 12 months (a possible 159.86% upside). 16 analyst firms have reported ratings in the last year.
Current Stock Price for Beam Therapeutics (BEAM)?
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $21.55 last updated October 4, 2023 at 11:33 PM UTC.
Does Beam Therapeutics (BEAM) pay a dividend?
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
When is Beam Therapeutics (NASDAQ:BEAM) reporting earnings?
Beam Therapeutics’s Q3 earnings are confirmed for Monday, November 6, 2023.
Is Beam Therapeutics (BEAM) going to split?
There is no upcoming split for Beam Therapeutics.
What sector and industry does Beam Therapeutics (BEAM) operate in?
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Beam Therapeutics Stock (NASDAQ:BEAM), Quotes and News Summary
Beam Therapeutics Stock (NASDAQ: BEAM) stock price, news, charts, stock research, profile.
| Open22.470 | Close21.540 |
| Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
| Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.340 | (EXPECTED) 2023-11-06 | |||||
| REV | 17.490M | ||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.420 | -1.080 | 0.3400 | ||||
| REV | 18.050M | 20.116M | 2.066M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-09-13 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
| 2023-08-29 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
| 2023-08-09 | Barclays | Gena Wang | Maintains | Equal-WeightEqual-Weight | Lowers | 41.00 | 35.00 |
| 2023-08-09 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 46.00 | 47.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| BEAM | Beam Therapeutics | -3.75% | 1.7B |
| IDYA | IDEAYA Biosciences | -0.16% | 1.5B |
| RARE | Ultragenyx Pharmaceutical | -3.44% | 2.4B |
| ZNTL | Zentalis Pharma | 3.11% | 1.4B |
| PRTA | Prothena Corp | -4.65% | 2.4B |
How do I buy Beam Therapeutics (BEAM) stock?
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Who are Beam Therapeutics's (BEAM) competitors?
Other companies in Beam Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Zentalis Pharma (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA) and SpringWorks Therapeutics (NASDAQ:SWTX).
What is the target price for Beam Therapeutics (BEAM) stock?
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on Wednesday, September 13, 2023. The analyst firm set a price target for 56.00 expecting BEAM to rise to within 12 months (a possible 159.86% upside). 16 analyst firms have reported ratings in the last year.
Current Stock Price for Beam Therapeutics (BEAM)?
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $21.55 last updated October 4, 2023 at 11:33 PM UTC.
Does Beam Therapeutics (BEAM) pay a dividend?
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
When is Beam Therapeutics (NASDAQ:BEAM) reporting earnings?
Beam Therapeutics’s Q3 earnings are confirmed for Monday, November 6, 2023.
Is Beam Therapeutics (BEAM) going to split?
There is no upcoming split for Beam Therapeutics.
What sector and industry does Beam Therapeutics (BEAM) operate in?
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Beam Therapeutics Stock (NASDAQ:BEAM), Quotes and News Summary
Beam Therapeutics Stock (NASDAQ: BEAM) stock price, news, charts, stock research, profile.
| Open22.470 | Close21.540 |
| Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
| Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.340 | (EXPECTED) 2023-11-06 | |||||
| REV | 17.490M | ||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.420 | -1.080 | 0.3400 | ||||
| REV | 18.050M | 20.116M | 2.066M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-09-13 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
| 2023-08-29 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
| 2023-08-09 | Barclays | Gena Wang | Maintains | Equal-WeightEqual-Weight | Lowers | 41.00 | 35.00 |
| 2023-08-09 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 46.00 | 47.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| BEAM | Beam Therapeutics | -3.75% | 1.7B |
| IDYA | IDEAYA Biosciences | -0.16% | 1.5B |
| RARE | Ultragenyx Pharmaceutical | -3.44% | 2.4B |
| ZNTL | Zentalis Pharma | 3.11% | 1.4B |
| PRTA | Prothena Corp | -4.65% | 2.4B |
How do I buy Beam Therapeutics (BEAM) stock?
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Who are Beam Therapeutics's (BEAM) competitors?
Other companies in Beam Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Zentalis Pharma (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA) and SpringWorks Therapeutics (NASDAQ:SWTX).
What is the target price for Beam Therapeutics (BEAM) stock?
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on Wednesday, September 13, 2023. The analyst firm set a price target for 56.00 expecting BEAM to rise to within 12 months (a possible 159.86% upside). 16 analyst firms have reported ratings in the last year.
Current Stock Price for Beam Therapeutics (BEAM)?
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $21.55 last updated October 4, 2023 at 11:33 PM UTC.
Does Beam Therapeutics (BEAM) pay a dividend?
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
When is Beam Therapeutics (NASDAQ:BEAM) reporting earnings?
Beam Therapeutics’s Q3 earnings are confirmed for Monday, November 6, 2023.
Is Beam Therapeutics (BEAM) going to split?
There is no upcoming split for Beam Therapeutics.
What sector and industry does Beam Therapeutics (BEAM) operate in?
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Beam Therapeutics Stock (NASDAQ:BEAM), Quotes and News Summary
Beam Therapeutics Stock (NASDAQ: BEAM) stock price, news, charts, stock research, profile.
| Open22.470 | Close21.540 |
| Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
| Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.340 | (EXPECTED) 2023-11-06 | |||||
| REV | 17.490M | ||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.420 | -1.080 | 0.3400 | ||||
| REV | 18.050M | 20.116M | 2.066M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-09-13 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
| 2023-08-29 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
| 2023-08-09 | Barclays | Gena Wang | Maintains | Equal-WeightEqual-Weight | Lowers | 41.00 | 35.00 |
| 2023-08-09 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 46.00 | 47.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| BEAM | Beam Therapeutics | -3.75% | 1.7B |
| IDYA | IDEAYA Biosciences | -0.16% | 1.5B |
| RARE | Ultragenyx Pharmaceutical | -3.44% | 2.4B |
| ZNTL | Zentalis Pharma | 3.11% | 1.4B |
| PRTA | Prothena Corp | -4.65% | 2.4B |
How do I buy Beam Therapeutics (BEAM) stock?
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Who are Beam Therapeutics's (BEAM) competitors?
Other companies in Beam Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Zentalis Pharma (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA) and SpringWorks Therapeutics (NASDAQ:SWTX).
What is the target price for Beam Therapeutics (BEAM) stock?
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on Wednesday, September 13, 2023. The analyst firm set a price target for 56.00 expecting BEAM to rise to within 12 months (a possible 159.86% upside). 16 analyst firms have reported ratings in the last year.
Current Stock Price for Beam Therapeutics (BEAM)?
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $21.55 last updated October 4, 2023 at 11:33 PM UTC.
Does Beam Therapeutics (BEAM) pay a dividend?
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
When is Beam Therapeutics (NASDAQ:BEAM) reporting earnings?
Beam Therapeutics’s Q3 earnings are confirmed for Monday, November 6, 2023.
Is Beam Therapeutics (BEAM) going to split?
There is no upcoming split for Beam Therapeutics.
What sector and industry does Beam Therapeutics (BEAM) operate in?
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Beam Therapeutics Stock (NASDAQ:BEAM), Quotes and News Summary
Beam Therapeutics Stock (NASDAQ: BEAM) stock price, news, charts, stock research, profile.
| Open22.470 | Close21.540 |
| Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
| Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.340 | (EXPECTED) 2023-11-06 | |||||
| REV | 17.490M | ||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.420 | -1.080 | 0.3400 | ||||
| REV | 18.050M | 20.116M | 2.066M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-09-13 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
| 2023-08-29 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
| 2023-08-09 | Barclays | Gena Wang | Maintains | Equal-WeightEqual-Weight | Lowers | 41.00 | 35.00 |
| 2023-08-09 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 46.00 | 47.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| BEAM | Beam Therapeutics | -3.75% | 1.7B |
| IDYA | IDEAYA Biosciences | -0.16% | 1.5B |
| RARE | Ultragenyx Pharmaceutical | -3.44% | 2.4B |
| ZNTL | Zentalis Pharma | 3.11% | 1.4B |
| PRTA | Prothena Corp | -4.65% | 2.4B |
How do I buy Beam Therapeutics (BEAM) stock?
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Who are Beam Therapeutics's (BEAM) competitors?
Other companies in Beam Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Zentalis Pharma (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA) and SpringWorks Therapeutics (NASDAQ:SWTX).
What is the target price for Beam Therapeutics (BEAM) stock?
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on Wednesday, September 13, 2023. The analyst firm set a price target for 56.00 expecting BEAM to rise to within 12 months (a possible 159.86% upside). 16 analyst firms have reported ratings in the last year.
Current Stock Price for Beam Therapeutics (BEAM)?
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $21.55 last updated October 4, 2023 at 11:33 PM UTC.
Does Beam Therapeutics (BEAM) pay a dividend?
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
When is Beam Therapeutics (NASDAQ:BEAM) reporting earnings?
Beam Therapeutics’s Q3 earnings are confirmed for Monday, November 6, 2023.
Is Beam Therapeutics (BEAM) going to split?
There is no upcoming split for Beam Therapeutics.
What sector and industry does Beam Therapeutics (BEAM) operate in?
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Beam Therapeutics Stock (NASDAQ:BEAM), Quotes and News Summary
Beam Therapeutics Stock (NASDAQ: BEAM) stock price, news, charts, stock research, profile.
| Open22.470 | Close21.540 |
| Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
| Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.340 | (EXPECTED) 2023-11-06 | |||||
| REV | 17.490M | ||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.420 | -1.080 | 0.3400 | ||||
| REV | 18.050M | 20.116M | 2.066M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-09-13 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
| 2023-08-29 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
| 2023-08-09 | Barclays | Gena Wang | Maintains | Equal-WeightEqual-Weight | Lowers | 41.00 | 35.00 |
| 2023-08-09 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 46.00 | 47.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| BEAM | Beam Therapeutics | -3.75% | 1.7B |
| IDYA | IDEAYA Biosciences | -0.16% | 1.5B |
| RARE | Ultragenyx Pharmaceutical | -3.44% | 2.4B |
| ZNTL | Zentalis Pharma | 3.11% | 1.4B |
| PRTA | Prothena Corp | -4.65% | 2.4B |
How do I buy Beam Therapeutics (BEAM) stock?
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Who are Beam Therapeutics's (BEAM) competitors?
Other companies in Beam Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Zentalis Pharma (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA) and SpringWorks Therapeutics (NASDAQ:SWTX).
What is the target price for Beam Therapeutics (BEAM) stock?
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on Wednesday, September 13, 2023. The analyst firm set a price target for 56.00 expecting BEAM to rise to within 12 months (a possible 159.86% upside). 16 analyst firms have reported ratings in the last year.
Current Stock Price for Beam Therapeutics (BEAM)?
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $21.55 last updated October 4, 2023 at 11:33 PM UTC.
Does Beam Therapeutics (BEAM) pay a dividend?
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
When is Beam Therapeutics (NASDAQ:BEAM) reporting earnings?
Beam Therapeutics’s Q3 earnings are confirmed for Monday, November 6, 2023.
Is Beam Therapeutics (BEAM) going to split?
There is no upcoming split for Beam Therapeutics.
What sector and industry does Beam Therapeutics (BEAM) operate in?
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Beam Therapeutics Stock (NASDAQ:BEAM), Quotes and News Summary
Beam Therapeutics Stock (NASDAQ: BEAM) stock price, news, charts, stock research, profile.
| Open22.470 | Close21.540 |
| Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
| Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.340 | (EXPECTED) 2023-11-06 | |||||
| REV | 17.490M | ||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.420 | -1.080 | 0.3400 | ||||
| REV | 18.050M | 20.116M | 2.066M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-09-13 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
| 2023-08-29 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
| 2023-08-09 | Barclays | Gena Wang | Maintains | Equal-WeightEqual-Weight | Lowers | 41.00 | 35.00 |
| 2023-08-09 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 46.00 | 47.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| BEAM | Beam Therapeutics | -3.75% | 1.7B |
| IDYA | IDEAYA Biosciences | -0.16% | 1.5B |
| RARE | Ultragenyx Pharmaceutical | -3.44% | 2.4B |
| ZNTL | Zentalis Pharma | 3.11% | 1.4B |
| PRTA | Prothena Corp | -4.65% | 2.4B |
How do I buy Beam Therapeutics (BEAM) stock?
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Who are Beam Therapeutics's (BEAM) competitors?
Other companies in Beam Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Zentalis Pharma (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA) and SpringWorks Therapeutics (NASDAQ:SWTX).
What is the target price for Beam Therapeutics (BEAM) stock?
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on Wednesday, September 13, 2023. The analyst firm set a price target for 56.00 expecting BEAM to rise to within 12 months (a possible 159.86% upside). 16 analyst firms have reported ratings in the last year.
Current Stock Price for Beam Therapeutics (BEAM)?
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $21.55 last updated October 4, 2023 at 11:33 PM UTC.
Does Beam Therapeutics (BEAM) pay a dividend?
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
When is Beam Therapeutics (NASDAQ:BEAM) reporting earnings?
Beam Therapeutics’s Q3 earnings are confirmed for Monday, November 6, 2023.
Is Beam Therapeutics (BEAM) going to split?
There is no upcoming split for Beam Therapeutics.
What sector and industry does Beam Therapeutics (BEAM) operate in?
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Beam Therapeutics Stock (NASDAQ:BEAM), Quotes and News Summary
Beam Therapeutics Stock (NASDAQ: BEAM) stock price, news, charts, stock research, profile.
| Open22.470 | Close21.540 |
| Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
| Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.340 | (EXPECTED) 2023-11-06 | |||||
| REV | 17.490M | ||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.420 | -1.080 | 0.3400 | ||||
| REV | 18.050M | 20.116M | 2.066M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-09-13 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
| 2023-08-29 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
| 2023-08-09 | Barclays | Gena Wang | Maintains | Equal-WeightEqual-Weight | Lowers | 41.00 | 35.00 |
| 2023-08-09 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 46.00 | 47.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| BEAM | Beam Therapeutics | -3.75% | 1.7B |
| IDYA | IDEAYA Biosciences | -0.16% | 1.5B |
| RARE | Ultragenyx Pharmaceutical | -3.44% | 2.4B |
| ZNTL | Zentalis Pharma | 3.11% | 1.4B |
| PRTA | Prothena Corp | -4.65% | 2.4B |
How do I buy Beam Therapeutics (BEAM) stock?
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Who are Beam Therapeutics's (BEAM) competitors?
Other companies in Beam Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Zentalis Pharma (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA) and SpringWorks Therapeutics (NASDAQ:SWTX).
What is the target price for Beam Therapeutics (BEAM) stock?
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on Wednesday, September 13, 2023. The analyst firm set a price target for 56.00 expecting BEAM to rise to within 12 months (a possible 159.86% upside). 16 analyst firms have reported ratings in the last year.
Current Stock Price for Beam Therapeutics (BEAM)?
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $21.55 last updated October 4, 2023 at 11:33 PM UTC.
Does Beam Therapeutics (BEAM) pay a dividend?
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
When is Beam Therapeutics (NASDAQ:BEAM) reporting earnings?
Beam Therapeutics’s Q3 earnings are confirmed for Monday, November 6, 2023.
Is Beam Therapeutics (BEAM) going to split?
There is no upcoming split for Beam Therapeutics.
What sector and industry does Beam Therapeutics (BEAM) operate in?
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.